Subconjunctival adalimumab for treatment of dry eye disease in Sjögren’s syndrome

Objective To describe the use of subconjuctival administration anti-tumor necrosis factor agent adalimumab for treatment dry eye in patients with Sjögren’s syndrome, and to investigate conjunctival healing. Methods Prospective, nonrandomized, noncomparative interventional case series including consecutive syndrome disease treated subconjunctival adalimumab, who were refractory conventional treatment. Patients infectious ocular surface involvement or structural changes tear pathway eyelids excluded. Data recorded included age, sex, [...]